Innovative Platform Aqtual's proprietary cell-free DNA technology for precision medicine offers significant opportunities to collaborate with healthcare providers and diagnostic companies seeking advanced solutions for oncology and chronic disease management.

Growing Funding Base Recent Series B financing of 31 million USD indicates strong investor confidence, providing resources for expanding research initiatives and commercializing their biotechnological innovations, which can be leveraged for strategic partnerships.

Clinical Development Efforts The launch of the PRIMA-102 proof-of-concept clinical study demonstrates active clinical validation, opening doors for relationships with research institutions and pharma companies interested in early-stage diagnostics and targeted therapies.

Sustainability Focus Aqtual's commitment to improving treatment precision aligns with market trends favoring personalized healthcare, making it an attractive partner for organizations focused on innovative, patient-centric solutions.

Market Expansion Opportunity With its focus on liquid biopsies for rheumatoid arthritis and on oncology, Aqtual is positioned to tap into growing segments within the biotechnology sector, offering potential sales channels for medical device firms, research collaborations, and healthcare service providers.